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Purpose: A new carboxymethylcellulose (CMC)-containing ophthalmic formulation of 0.45% 
ketorolac, pH 6.8 (Acuvail®) was recently developed for treatment of inflammation and pain 
after cataract surgery. This study compared pharmacokinetics of the new formulation with that 
of a prior formulation, 0.4% ketorolac, pH 7.4 (Acular LS®).
Methods: Ketorolac formulations were administered bilaterally (35 µL) to female New Zealand 
White rabbits. Samples from aqueous humor and iris-ciliary body were collected at multiple time 
points, and ketorolac was quantified using liquid chromatography-tandem mass spectrometry.
Results: In aqueous humor, the peak concentration (Cmax) and area under the concentration-time 
curve (AUC0–t) of ketorolac were, respectively, 389 ng/mL and 939 ng·h/mL following admin-
istration of the CMC-containing 0.45% ketorolac, pH 6.8, and 211 ng/mL and 465 ng·hr/mL 
following administration of the 0.4% ketorolac, pH 7.4. In iris-ciliary body, Cmax and AUC0–t 
of ketorolac were, respectively 450 ng/g and 2040 ng·h/g after administration of the CMC-
containing 0.45% ketorolac, pH 6.8, and 216 ng/g and 699 ng·h/g after administration of the 
0.4% ketorolac, pH 7.4. PK simulations predicted an AUC0–τ of 2910 ng·h/g for twice daily, 
CMC-containing 0.45% ketorolac, pH 6.8, compared to 725 ng·h/g for 4 times daily, 0.4% 
ketorolac, pH 7.4.
Conclusions: The CMC-containing formulation of 0.45% ketorolac, pH 6.8, increased ketorolac 
bioavailability by 2-fold in aqueous humor and by 3-fold in iris-ciliary body in comparison to 
the 0.4% ketorolac, pH 7.4, allowing a reduced dosing schedule from 4 times daily to twice 
daily.
Keywords: Acuvail, Acular LS, inflammation, ketorolac, ocular pharmacokinetics, twice-daily 
dosing
Introduction
Ketorolac is a nonsteroidal anti-inflammatory drug with analgesic and anti-
  inflammatory properties.1 Currently available ophthalmic formulations of ketorolac 
include a 0.5% solution (Acular®; Allergan Inc., Irvine, CA), indicated for treatments 
of inflammation following cataract extraction and ocular itching due to seasonal 
allergic conjunctivitis, and a 0.4% solution, (Acular LS®; Allergan Inc.), indicated 
for treatment of pain and burning/stinging after corneal refractive surgery.2,3 Both of 
these ketorolac formulations are indicated for instillation 4 times daily.
Several clinical studies have demonstrated the safety and efficacy of the 0.5% 
and 0.4% ketorolac formulations for the alleviation of ocular inflammation and 
pain,   prevention and treatment of cystoid macular edema, and/or prevention of Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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intraoperative miosis in ocular surgery patients.4–10 With 
20% less active ingredient, the 0.4% ketorolac was 
  demonstrated to be equivalent in potency to the 0.5% 
ketorolac in animal and human studies.8,11 Both the 0.4% and 
0.5% ketorolac solutions, however, contain the preservative 
benzalkonium chloride (BAK), the surfactant octoxynol-40, 
and the metal-chelating agent sodium edetate and are 
  associated with a high incidence of burning and stinging 
upon instillation.2,3,9
The formulation of ophthalmic solutions can profoundly 
affect the safety, bioavailability, and tissue distribution of 
the active ingredients. To enhance the ocular bioavailability 
and tolerability of ketorolac, various modifications were 
made to the 0.4% ketorolac formulation, which included 
increasing the concentration of active ingredient, lowering 
formulation pH, adding carboxymethylcellulose (CMC), 
and excluding preservative, surfactant, and metal chelating 
agents. The purpose of this study was to evaluate the impact 
of these modifications on the ocular pharmacokinetics (PK) 
of ketorolac.
Methods
Ketorolac formulations
The ophthalmic solution of 0.4% ketorolac (Acular LS) 
  contains 0.006% BAK, sodium chloride, 0.015% edetate 
disodium, octoxynol-40, purified water, and hydrochlo-
ric acid and/or sodium hydroxide to adjust the pH to 
approximately 7.4.2 For the formulations tested here: a) the 
preservative BAK, the metal-chelating agent edetate diso-
dium, and the surfactant octoxynol-40 were omitted; b) CMC 
was added as a viscosity agent; and c) the concentration of 
ketorolac was increased to 0.45%. The pH was adjusted by 
the addition of hydrochloric acid or sodium hydroxide.
PK sampling
A 35 µL aliquot of test formulations or 0.4% ketorolac was 
topically administered to each eye of female New Zealand 
White rabbits (Covance Research Products Inc., Denver, PA). 
Samples from aqueous humor (n = 6 eyes of 3 rabbits/ 
timepoint) were collected at 1, 2, and 4 hours postdose. 
  Samples from iris-ciliary body (n = 4 eyes of 2 rabbits/
timepoint) were collected at 1, 2, 4, and 8 hours postdose. 
Animals were euthanized with an intravenous injection 
of sodium pentobarbital. All protocols were reviewed 
and approved by the Institutional Animal Care and Use 
  Committee, and the study conformed to the principles of 
animal use set forth by the Association for Research in 
Vision and Ophthalmology Statement for Use of Animals in 
Ophthalmic and Vision Research.
Ketorolac extraction and quantification
Ketorolac concentrations in aqueous humor and iris-
ciliary body were determined after liquid-liquid extraction 
by a liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). Iris-ciliary body samples were prepared for 
extraction by homogenization in 1 mL of 50% methanol. 
Finasteride (500 ng/mL; 10 µL) was then added to 50 µL 
aliquots of aqueous humor and to 300 µL aliquots of the 
homogenized iris-ciliary body samples. Since stable-  isotope 
labeled ketorolac is not available, finasteride, which has 
an approximately similar retention time on liquid chro-
matography, was used as an internal standard. Ketorolac 
was extracted with methyl tert-butyl ether. The organic 
extracts were evaporated to dryness, and the precipitates 
were reconstituted with 40% acetonitrile for injection onto 
the LC-MS/MS system utilizing an atmospheric-pressure 
chemical ionization heated nebulizer source. Ketorolac 
quantification was conducted in the positive ion multiple 
reaction–monitoring mode.
Data analysis
Thermo Electron WatsonTM (Thermo Electron Corporation, 
Waltham, MA) software was used for PK calculations. All 
samples were analyzed for peak concentrations (Cmax), time 
to Cmax (Tmax), and area under the concentration-time curve 
from time 0 to the sampling time (AUC0-t) using the random 
method for nonsequential sampling. Relative bioavailability 
(relative %F) was expressed as the percentage of the AUC0-t 
of the 0.4% ketorolac following a single ocular instillation 
(35 µL). PK simulations were performed using WinNonlin 
Enterprise (Pharsight, Mountain View, CA).
statistical analysis
Between-group differences in iris-ciliary body Cmax were 
evaluated by one-way analysis of variance (ANOVA) and 
Dunett’s multiple comparison test. P , 0.05 was considered 
a statistically significant difference.
Results
effects of CMC and ph on ketorolac  
PK in aqueous humor
The PK of the CMC-containing test formulations at dif-
ferent pH were compared to that of the 0.4% ketorolac 
(Acular LS) (Table 1). At pH = 7.4, the inclusion of CMC Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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as well as a 12.5% increase in ketorolac concentration 
enhanced   ketorolac bioavailability in aqueous humor 
by 35%   compared to ketorolac 0.4% (AUC0–4 [SEM] of 
627 ± 51 ng·h/mL versus 465 ± 65 ng·h/mL, respectively). 
Decreasing the pH from 7.4 to 6.8 in combination with 
the addition of CMC enhanced ketorolac bioavailability in 
aqueous humor by 2-fold compared to ketorolac   exposure 
  following the 0.4% ketorolac administration (AUC0–4 
[SEM] of 939 ± 163 ng·h/mL versus 465 ± 65 ng·h/mL, 
respectively) (Table 1). Temporal kinetics of aqueous 
ketorolac concentrations   following instillation of the CMC-
containing 0.45% ketorolac, pH 6.8, or the 0.4% ketorolac, 
pH 7.4, are presented in Figure 1a.
effects of CMC and ph on ketorolac  
PK in iris-ciliary body
In iris-ciliary body, the Cmax (SD) and AUC0–8 (SEM) 
of   ketorolac were, respectively, 450 ± 117 ng/g and 
2040 ± 240 ng·h/g following administration of the CMC-
containing 0.45% ketorolac, pH 6.8, and 216 ± 43 ng/g and 
699 ± 74 ng·h/g after administration of the 0.4% ketorolac 
(Table 2). The between-group difference in ketorolac Cmax was 
statistically significant (P , 0.05). Overall, ketorolac bio-
availability increased by 3-fold in iris ciliary body following 
administration of the CMC-containing 0.45% ketorolac, pH 
6.8, compared to the 0.4% ketorolac, pH 7.4. Temporal kinet-
ics of ketorolac concentrations in iris-ciliary body following 
instillation of the CMC-containing 0.45% ketorolac, pH 6.8, 
or the 0.4% ketorolac, pH 7.4, are presented in Figure 1b.
PK simulation of ketorolac 
concentrations following multiple dose 
administration over a 24-hour period
PK simulations of multiple-dose regimens derived from 
data collected following a single dose predicted an AUC0-τ 
of 2910 ng·h/g for twice daily, CMC-containing 0.45% 
ketorolac, pH 6.8, compared to 725 ng·h/g for 4 times daily 
0.4% ketorolac, pH 7.4 (Figure 2).
Discussion
Ketorolac ophthalmic formulations have been used success-
fully since 1997 for the control of inflammation after cataract 
surgery and the reduction of pain after refractive surgery. 
However, both the 0.4% ketorolac solution (Acular LS) and 
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Figure 1 Temporal kinetics of ketorolac concentrations (±seM) following a single 
topical administration of the CMC-containing 0.45% ketorolac, ph 6.8 (Acuvail), and 
the 0.4% ketorolac, ph 7.4 (Acular Ls), in aqueous humor (a) and iris-ciliary body (b).
Abbreviation: CMC, carboxymethylcellulose.
Table 1 Aqueous humor pharmacokinetics of ketorolac following administration of the 0.4% ketorolac, ph 7.4 (Acular Ls), and the 
CMC-containing 0.45% ketorolac, ph 6.8 (Acuvail), formulations at varying ph
Ketorolac 
(%w/v)
CMC pH Tmax 
(hour)
Cmax 
(ng/mL [SD])
AUC0–4 
(ng.h/mL [SEM])
Relative %F
0.40 - 7.4 1.0 211 (106) 465 (65) 100
0.45 + 7.4 2.0 265 (71) 627 (51) 135
0.45 + 7.2 1.0 240 (84) 619 (50) 133
0.45 + 7.0 1.0 268 (125) 658 (73) 142
0.45 + 6.8 2.0 389 (258) 939 (163) 202
Abbreviations: AUC0–4, area under the concentration-time curve from time 0 to 4 hours; CMC, carboxymethylcellulose; Cmax, peak concentration; relative %F, percentage 
of the AUC0–4 value compared to that of the 0.4% ketorolac; seM, standard error of the mean; sD, standard deviation; Tmax, time to Cmax.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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the 0.5% ketorolac solution (Acular) were   associated with 
a high incidence of burning and stinging upon instillation 
as reported in their package inserts (“20%–40%” and “up 
to 40%”, respectively).2,3 The high rate of burning and 
stinging may negatively impact patient acceptance and 
compliance.
The most important finding of the current study was that 
the CMC-containing 0.45% ketorolac, pH 6.8 (Acuvail®; 
Allergan Inc., Irvine, CA), delivered higher ketorolac concen-
trations to aqueous humor and iris-ciliary body than did the 
0.4% ketorolac, pH 7.4. The new formulation also provided 
greater aqueous humor exposure to ketorolac in comparison 
to historical PK data from the 0.5% ketorolac formulation, pH 
7.4 (AUC0–4 = 939 ng·h/mL versus AUC0–4 = 583 ng·h/mL, 
respectively).12 The 0.5% ketorolac formulation, pH 7.4, 
achieves ,4% absolute ocular bioavailability in the anterior 
chamber.12
Low ocular bioavailability following topical adminis-
tration is a well recognized challenge in ophthalmic drug 
delivery, which is attributed to the drainage of the majority 
of drug through the nasolacrimal duct. In comparison to 
the anterior chamber, it is even more difficult for topical 
NSAIDs to penetrate into and maintain therapeutic levels 
in the posterior chamber. Previous studies demonstrated 
that the 0.4% ketorolac penetrated into vitreous and signifi-
cantly lowered vitreous prostaglandin E2 levels compared to 
  control.13 Further studies are warranted to evaluate whether 
the new 0.45% formulation can deliver higher   concentrations 
of ketorolac into the posterior chamber compared to the 
0.4% ketorolac.
In this study, factors that contributed to the improve-
ment of ketorolac delivery into ocular tissues were a small 
increase in ketorolac concentration, the addition of CMC, 
and a decrease in formulation pH. CMC is a cellulose 
derivative that is soluble in aqueous solutions and is used to 
provide viscosity without gelling. CMC increases the ocu-
lar residence time of topical ophthalmic drugs and thereby 
enhances ocular absorption.14–16 In our study, the addition of 
CMC to a formulation of 0.45% ketorolac at pH = 7.4 sub-
stantially increased ketorolac absorption into aqueous humor 
in comparison to the CMC-free 0.4% ketorolac, pH 7.4. An 
additional benefit of the use of CMC in ophthalmic solutions 
is its ability to promote corneal epithelial wound healing.17 
This feature is important for ophthalmic treatments   following 
cataract surgery.
The un-ionized form of a drug is more readily available for 
ocular absorption than the ionized form. The primary   factor 
affecting ionization is pH.18 With a pKa of 3.5,   ketorolac is 
mostly ionized in the pH range of 6.8 to 7.4, according to the 
Henderson–Hasselbalch equation, pH = pKa + log[A-]/[HA], 
where [A-] and [HA] represent the concentration of ionized 
and un-ionized ketorolac, respectively.18 As the pH is decreased 
from 7.4 to 6.8, relatively more ketorolac becomes un-ionized 
and, as a corollary, bioavailable. For the CMC-containing 0.45% 
ketorolac formulation, a shift from pH 7.4 to pH 6.8 results in 
4-fold higher percentage of un-ionized drug that is available for 
absorption (0.0125% versus 0.05%, respectively).
Other formulation modifications included the omission 
of BAK, edetate disodium, and octoxynol-40. BAK has been 
shown to promote absorption of some ophthalmic drugs.19 
The impact of BAK on ocular absorption of ketorolac is, 
however, controversial. In vivo, BAK did not improve the 
Table 2 Pharmacokinetics of ketorolac in iris-ciliary body following administrations of the CMC-containing 0.45% ketorolac, ph 6.8 
(Acuvail), and the 0.4% ketorolac, ph 7.4 (Acular Ls)
Tmax (hour) Cmax (ng/g [SD]) AUC0–t (ng.h/g [SEM]) Relative %F
CMC-containing 0.45% 
ketorolac, ph 6.8
1.0 450a (117) 2040 (240) 292
0.4% ketorolac, ph 7.4 1.0 216 (43) 699 (74) 100
Note: aP , 0.05 compared to the 0.4% ketorolac, ph 7.4 (Acular Ls).
Abbreviations: AUC0–4, area under the concentration-time curve from time 0 to 4 hours; CMC, carboxymethylcellulose; Cmax, peak concentration; relative %F, percentage 
of the AUC0–4 value compared to that of the 0.4% ketorolac; seM, standard error of the mean; sD, standard deviation; Tmax, time to Cmax.
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Figure  2  simulation  of  ketorolac  concentrations  in  iris-ciliary  body  following 
multiple topical administrations of the CMC-containing 0.45% ketorolac, ph 6.8 
(Acuvail), and the 0.4% ketorolac, ph 7.4 (Acular Ls).
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bioavailability of ketorolac in rabbits with intact corneas 
and decreased ocular absorption of ketorolac in rabbits with 
  de-epithelialized corneas.20 In vitro, however, BAK improved 
the rate of ocular absorption of ketorolac.21   Nevertheless, 
reformulation of ketorolac without BAK, edetate disodium, 
and octoxynol-40 may improve tolerability and ocular 
comfort.
With a longer retention time and higher bioavailability 
on the ocular surface, the CMC-containing 0.45% ketorolac, 
pH 6.8, exhibits the potential for use at longer intervals. 
PK simulations indicated that twice daily instillation of the 
new formulation may provide greater drug exposure than 
does 4 times daily instillation of 0.4% ketorolac, pH 7.4, 
in iris-ciliary body over a 24-hour period. Considering the 
omission of the preservative, surfactant, and metal-chelating 
agents, this finding suggests that the CMC-containing 
0.45% ketorolac, pH 6.8, is likely to provide a similar 
  efficacy to those of the 0.4% and 0.5% formulations in 
reducing inflammation and pain but with improved ocular 
comfort at a reduced dosing frequency. Pivotal phase 3   trials 
have recently demonstrated that twice daily instillation of 
the CMC-containing 0.45% ketorolac, pH 6.8, was well 
tolerated and effectively treated both inflammation and pain 
in cataract surgery patients.22 Based on these findings, the 
Food and Drug Administration approved twice-daily CMC-
containing 0.45% ketorolac for treatment of ocular inflam-
mation and pain following cataract surgery.23 In addition to 
convenience, a less frequent dosing regimen may increase 
patient compliance and adherence to the recommended 
dosing schedule.24,25 Together these data demonstrate that 
by targeting formulation modifications to the small frac-
tion of drug available for absorption, substantial effects 
on increasing ocular penetration can be observed. Further 
studies are warranted to compare the PK and efficacy of 
the new ketorolac formulation to those of other ophthalmic 
NSAIDs for the treatment of prostaglandin-mediated ocular 
inflammatory conditions.
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